Genetic predisposition for the development of complications in patients after coronary artery stenting

Dana Taizhanova 1, Akerke Kalimbetova 1 * , Aliya Toleuova 1, Rosa Bodaubay 1, Olga Visternichan 1, Aigul Kurmanova 1
More Detail
1 №1 Department of Internal Diseases, Karaganda Medical University, Karaganda, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 4, Issue 54, pp. 6-9.
Download Full Text (PDF)


In the review the authors analyzed the literature data on the state of knowledge of the problems of genetic polymorphisms CYP2C19 gene response to clopidogrel in patients with acute coronary syndrome. Despite on the technological advances and the widespread use of coronary stenting, restenosis at the site of angioplasty remains the main factor limiting its long-term effectiveness. We made the literature review of the state of the study of the genetic polymorphism of the CYP2C19 gene for a response to clopidogrel in patients with acute coronary syndrome and percutaneous coronary intervention. To achieve this goal, a systematic search and subsequent analysis of publications and online resources were carried out. All publications are indexed in the PubMed, Medline, e-Library, CoogleScholar.


Taizhanova D, Kalimbetova A, Toleuova A, Bodaubay R, Visternichan O, Kurmanova A. Genetic predisposition for the development of complications in patients after coronary artery stenting. Journal of Clinical Medicine of Kazakhstan. 2019;4(54):6-9.


  • Shalnova S.A. Analysis of mortality from cardiovascular diseases in 12 regions of the Russian Federation participating in the study "Epidemiology of cardiovascular diseases in various regions of Russia". Russian cardiol. journal. 2012; 5(97):-11.
  • Babunashvili А.М., Ivanov V.A., Biryukov S.A.Endoprosthetics (stenting) of coronary arteries of the heart. ASV. 2001; 699.
  • Ma X., Wu T., Robich M.P., Wang X., Wu H., Buchholz B., McCarthy S. Drug-eluting stents. Int. J. Clin. Exp. Med. 2010; 3(3):192-201.
  • Simonenko VB, Borisov IA, Bletkin AN, et al. Myocardial revascularization: coronary artery bypass grafting or stenting? Clinical medicine. 2008; 3:13-17.
  • Marchenko AB, Laryushina E.M. Role of N-oxide trimethylamine in the pathogenesis, diagnosis and prognosis of cardiovascular diseases. Medicine and Ecology. 2017; 1:41-47.
  • Ruygrok P.N., Webster M.W.I., de Valk V. Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. Circulation. 2001; 104 (19): 2289-2294.
  • Scott SA., Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 2011; 90(2):328-332
  • Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004; 59 (1):5-12 
  • Zhou H.H., Anthony L.B., Wood A.J., Wilkinson G.R. Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J ClinPharmacol. 1990; 30:471-475
  • de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol. Chem. 1994; 269(22):15419-15422
  • Li X.Q., Andersson T.B., Ahlstrom M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug MetabDispos. 2004; 2:821-827
  • Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss-offunction polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108:2244-2247
  • Abraham N.S., Hlatky M.A., Antman E.M., Bhatt D.L., Bjorkman D.J., Clark C.B. et al. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/ AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2010. 56(24):2051-2066
  • Sibbing D. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 2009; 30:916-922
  • Desta Z., Zhao X., Shin JG., Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002; 41:913-958.
  • Hulot J., Collet J., Silvain J. et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton PumpInhibitor Coadministration: A Systematic Meta-Analysis. J Am Coll Cardiol. 2010; 56(2):134-143.
  • Mega J., Close S., Wiviott S., Shen L., Hockett R., Brandt J., Walker J., Antman 114 E., Macias W., Braunwald., Sabatine M. Cytochrome p-450 polymorphisms, response to clopidogrel. N Engl J Med. 2009; 360:354-362.
  • Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108:2244-2247
  • Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. ClinPharmacokinet. 2002; 41:913-958
  • Frére, C., Cuisset, T., Gaborit B., Alessi, M.C. &Hulot, J.S. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J. Thromb. Haemost. 2009; 7:1409-1411
  • Wortham M., Czerwinski M., He L., Parkinson A., Wan Y.J. Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of abroad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos. 2007; 35(9):1700-1710.
  • Li Y., Tang H.L., Hu Y.F., Xie H.G. The gain-of-function variant allele CYP2C19*17: a double edged sword between thrombosis and bleeding in clopidogrel-treated patients. J. Thromb. Haemost. 2012; 10:199-206
  • Sibbing D. et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010; 121: 512-518
  • Geisler T. et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008; 9:1251-1259
  • Lewis J. et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J. Thromb. Haemost. 2013; e-pub ahead of print.
  • Simon T. et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009; 360:363-375
  • Sorich M.J., Polasek T.M. & Wiese M.D. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb. Haemost. 2012; 108(1):199-200
  • Sibbing D., Gebhard D., Koch W., Braun S., Stegherr J., Morath T. et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010; 8(8):1685-1693
  • Payan M, Tajik N, Rouini MR, Ghahremani MH. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med J Islam Repub Iran. 2015; 29:269.
  • Collet JP, Hulot JS, Cayla G et al: 067 CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics and clinical efficacy in post-myocardial infarction patients. Arch Cardiovasc Dis Supplements. 2012; 4:22